In addition to cytokine targeting, there is increasing interest in B lymphocyte
immunomodulation as these cells may mediate inflammation in RA via rheumatoid factors …

Although considerable progress has been made by adequate treatment with traditional
disease‐modifying antirheumatic drugs (DMARDs), therapy of rheumatoid arthritis (RA) still …

Rheumatoid arthritis (RA) has a prevalence of approximately 1%, making it the most
common inflammatory rheumatic disease. The outcome for RA patients has significantly …

Rheumatoid arthritis (RA) remains a major clinical problem, but treatments involving
biologics have revolutionized its management. They target pathogenically relevant cytokines …

Two decades ago, patients presenting with the heterogeneous condition termed rheumatoid
arthritis (RA), best thought of as a syndrome, had a variable, but often poor, prognosis. Since …

The therapeutic agents currently available to treat rheumatoid arthritis (RA)(disease-
modifying antirheumatic drugs [DMARDs]) generally were not mitially developed for treating …

The improvement of rheumatoid arthritis (RA) management has been strictly related to
methotrexate (MTX) long-term effectiveness, safety profile and its widespread use in clinical …

RA is an autoimmune disease of unknown aetiology that primarily targets synovial tissues,
cartilage and bone, and is the most common form of immune-mediated arthritis [1]. Although …

Although traditional disease modifying and biological response modifying agents are very
useful in controlling disease activity, limiting disease progression, and improving function in …

Rheumatoid arthritis (RA) is a chronic inflammatory condition affecting 1% of adults in the
developed world. 1 In addition to joint inflammation and damage, the systemic effects of RA …